Filter by

  • Publication Year
  • Availability
  • Attachment
  • Collection Type
    See More
  • General Material Designation
    See More
  • Location
    See More
  • Language
Found 6 from your keywords: subject="Beriate"
cover
Haemophilia, state of the art and new therapeutic opportunities, a regulatory…
Comment Share
Tomeo F

Haemophilia A and B are rare bleeding disorders. Over the past decades, they have been transformed from debilitating diseases to manageable conditions in the Western world. However, optimizing haemophilia care remains challenging in developing countries. Several challenges and unmet needs remain in the treatment of the haemophilia limiting the QoL of patients. These challenges are now being add…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Pathogen safety of Beriate
Comment Share
Gröner A

Plasma-derived factor VIII (FVIII) concentrates have been used successfully to treat haemophilia A since the late 1960s. To ensure the pathogen safety of the plasma-derived FVIII concentrate, Beriate® (formerly Beriate® P), donors of blood/plasma are carefully selected and all donations are screened for hepatitis B virus surface antigen (HBsAg), antibodies against HIV types 1 and 2 (HIV-1/HIV…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
How I treat children with haemophilia and inhibitors
Comment Share
Young G

Haemophilia is a serious inherited bleeding disorder resulting from a deficiency of coagulation factor VIII (haemophilia A) or coagulation factor IX (haemophilia B). While effective therapies have been developed to replace the missing factor and restore normal coagulation, they can lead to the development of neutralizing anti-drug antibodies, termed inhibitors, which significantly worsen morbid…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Acquired Hemophilia: A Report of 4 Cases
Comment Share
Karimi M

Acquired hemophilia A is very rare and often causes life-threatening hemorrhage. We report 4 cases of this disorder in different settings. Case1 received activated protrombin concentrate complex (aPCC) and the result was excellent

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Management of bleeding in acquired haemophilia A with recombinant activated f…
Comment Share
Di Capua M

Acquired haemophilia A (AHA) is a rare but clinically relevant bleeding disorder due to autoantibodies (inhibitors) against coagulation factor VIII (FVIII

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Management of Acquired Hemophilia: A Literature Review
Comment Share
Holme PA

Acquired hemophilia is a rare, but often severe, bleeding disorder caused by autoantibodies against a coagulation factor, usually factor VIII (FVIII). The most common clinical presentations are diffuse bruising, soft tissue bleeds, and hematuria

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-